Elezanumab
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa) . Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism[1][2].
Product Specifications
CAS Number
1791416-49-3
Product Name Alternative
ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)
UNSPSC
12352203
Target
TGF-beta/Smad
Type
Inhibitory Antibodies
Related Pathways
Stem Cell/Wnt; TGF-beta/Smad
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/elezanumab.html
Purity
99.91
Solubility
H2O
Smiles
[Elezanumab]
Molecular Weight
(146.44 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Mouse VEGF R1/Flt-1 Alexa Fluor 350 Antibody (Clone 141522)
Recombinant Enterobacteria phage T3 Gene 5.5 protein (5.5)